Tampa Bay Company Searching for Other Vaccine Methods
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, is in the pre-clinical phase of developing a vaccine they say would solve two critical problems when it comes to ending the pandemic.
“We grind this out every day,” said CEO Alan Joslyn. “We all want to go back to our normal lives.”
The first goal is to find a vaccine that does not have to be given by needle, but rather a patch or nasal spray. The second is to produce antibodies that last indefinitely, whereas the current length of protection is unknown.
Oragenics, which is based in Tampa but has a lab in Alachua, hopes fewer needles and longer-lasting certainty would bring that number down, particularly in rural areas.
Learn more about Tampa Bay Company Searching for Other Vaccine Methods.